NCT01761526

Study to Evaluate the Pharmacokinetics (PK), Safety, Tolerability of Single-Dose Transdermal Rotigotine in Japanese and Caucasian Healthy Male / Female Subjects

Parallel Group Trial to Evaluate the Pharmacokinetics and Safety / Tolerability of Single-Dose Treatment With Rotigotine Continuous Delivery System (10 cm2 / 4.5 mg) in Japanese and Caucasian Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: UCB BIOSCIENCES GmbH · Industry
• Sex: All
• Age: 20 Years – 45 Years
• Healthy volunteers: Accepted

Summary

To investigate the Pharmacokinetics (PK) of transdermally delivered Rotigotine in Japanese and Caucasian Female and Male Healthy Subjects.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Rotigotine transdermal patch	Rotigotine transdermal patch, single-dose application over 24 hours 2 mg /24 hours (10 cm2)

Timeline

• Start date: 2002-10-01
• Primary completion: 2002-10-01
• Completion: 2002-12-01
• First posted: 2013-01-04
• Last updated: 2014-10-20

Locations

1 site across 1 country: Germany